TABLE 3.
Costs and outcome results in the base case analysis.
Country | Results | Methylated status | Unmethylated status | ||
---|---|---|---|---|---|
RT alone | RT plus TMZ | RT alone | RT plus TMZ | ||
China | Costs (¥) | 33,900.05 | 153,290.52 | 29,170.33 | 124,889.19 |
Life-years | 0.8 | 1.28 | 0.77 | 0.93 | |
QALYs | 0.53 | 0.88 | 0.57 | 0.61 | |
ICER | 342,162.55 | 2,453,399.26 | |||
US | Costs ($) | 54,796.09 | 85,975.87 | 47,685.92 | 77,357.47 |
Life-years | 0.8 | 1.28 | 0.77 | 0.93 | |
QALYs | 0.53 | 0.88 | 0.57 | 0.61 | |
ICER | 89,358.51 a | 760,520.78 |
QALY: quality-adjusted life-years; ICER: incremental cost-effectiveness ratio; RT: radiotherapy; TMZ: temozolomide.
Below the willingness-to-pay threshold of $10000 per QALY gained.